FDA approves Roche drug for late-stage metastatic breast cancer
Feb 22 (Reuters) - U.S. health regulators said on Friday they have approved a new drug made by Roche Holding AG for some patients with late-stage metastatic breast cancer who have failed other therapies.
The U.S. Food and Drug Administration said it approved Kadcyla, also known as ado-trastuzumab emtansine, for patients whose cancer cells contain increased amounts of a protein known as HER2.
The drug's label will carry a boxed warning, the most serious possible, of the drug's potential to cause liver and heart toxicity and death. The drug can also cause life-threatening birth defects.
In clinical trials, patients who took the drug, known during its development process as T-DM1, survived an average of 30.9 months, compared with 25.1 months in the control group.
- FBI, Secret Service investigate reports of cyber attacks on U.S. banks
- Breakthrough hopes dented as Ukraine accuses Russia of new incursion |
- Gaza truce holding but Israel's Netanyahu under fire at home |
- Zach Galifianakis, Louis C.K. comedy show 'Baskets' picked up by FX
- U.S. seeks coalition against Islamic State, but military partners no sure bet